DrugPatentWatch Database Preview
Patent: 6,756,480
» See Plans and Pricing
Summary for Patent: 6,756,480
| Title: | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| Abstract: | The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP. In accordance with the present invention, modulators of PTH and PTHrP comprise: (a) a PTH/PTHrP modulating domain; and (b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the C-terminus of the PTH/PTHrP modulating domain. The vehicle and the PTH/PTHrP modulating domain may be linked through the N- or C-terminus of the PTH/PTHrP modulating domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter. Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein. Such peptides typically will be modulators of both PTH activity and PTHrP activity, although such techniques can be used to generate peptide sequences that serve as selective modulators (e.g., agonists of PTH activity but not PTHrP activity). |
| Inventor(s): | Kostenuik; Paul (Newbury Park, CA), Liu; Chuan-Fa (Longmont, CO), Lacey; David Lee (Newbury Park, CA) |
| Assignee: | Amgen Inc. (Thousand Oaks, CA) |
| Application Number: | 09/843,221 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,756,480
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 004 | 2015-01-23 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2020-04-27 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 003 | 2015-01-23 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2020-04-27 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 002 | 2015-01-23 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2020-04-27 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 001 | 2015-01-23 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2020-04-27 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 6,756,480
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200208518 | Start Trial |
| World Intellectual Property Organization (WIPO) | 0181415 | Start Trial |
| United States of America | 2003039654 | Start Trial |
| United States of America | 2004214996 | Start Trial |
| United States of America | 2005124537 | Start Trial |
| Slovakia | 15202002 | Start Trial |
| Poland | 359410 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
